Ok, Phase 1 data were encouraging, but the sample was small, only 35 patients. But 21% had a PSA decline > 30%, which is not bad at all compared to the usual results of immunotherapies for the prostate (<10%). There is a lot to do still, but it's a good starting point.
Prostate cancer, especially in advanced stages, has long resisted immunotherapy due to its “cold” nature, meaning it’s largely invisible to the immune system. Recent research, however, identifies a key reason: SPP1+ macrophages and adenosine signaling, both of which shield cancer cells from immune response. A new drug, ciforadenant, blocks adenosine’s effects, reactivating immune cells. In early trials, combining ciforadenant with atezolizumab has shown promise, especially in patients identified with an “Adenosine Gene Signature,” a biomarker for treatment response. This strategy offers new hope in overcoming prostate cancer’s immunotherapy resistance.
I link my own repository...I hope you don't mind! 😜
